Zydus Lifesciences has partnered with Synthon BV in a deal to develop, license, supply, and commercialize a novel oncology drug in the US. The agreement aims to target a $1.5 billion market, with ...
Zydus Lifesciences Ltd on Wednesday said it has signed an exclusive development, licensing, supply and commercialisation pact with Synthon BV of the Netherlands for a novel oncology product for an ...
Zydus Wellness Limited’s (ZWL’s) Q3FY25 numbers were mixed with revenue growing by 15% y-o-y to Rs. 462 crore (versus Rs. 435 crore expected), while OPM stood flat y-o-y at 3.1% (against ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Nippon India Small Cap Fund - Direct (IDCW) 530.87 28,90,897 0.93 Nippon India Small Cap Fund - Direct (G) 530.87 28,90,897 0.93 Nippon India Small Cap Fund - Direct ...
Under the terms of the agreement, Beihai Biotech will be responsible for the manufacturing and supply of the product while Zydus will be responsible for ... sales targets-based milestone payments and ...
Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain ...
The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
The inspection was conducted from February 10th to 14th, 2025. The inspection concluded with NIL observations," Zydus Lifesciences said in a regulatory filing. Zydus Lifesciences' US formulation sales ...
1 share(s) for every 1 shares held Zydus Lifesciences Ltd., incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 92,965.96 Crore) operating in Pharmaceuticals sector. Zydus ...
The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Zydus will be responsible for commercialization of the product in the US. Beihai Biotech will receive upfront payments, sales targets-based milestone payments and a share of BEIZRAY’s net profits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results